Epigenetic resistance to leukemia therapy
Nature Genetics
2014년3월3일

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia (T-ALL) is reported in a study published this week in Nature Genetics. This work highlights that drug resistance in this disease may be overcome by using drugs that target epigenetic regulators.
Michelle Kelliher, Bradley Bernstein and colleagues isolated human T-ALL cells that are resistant to gamma-secretase inhibitors, drugs that show transient therapeutic effects when used to treat T-ALL. They performed a screen to identify genes required for survival of resistant leukemia cells and identified chromatin regulators as being important in this survival process. They show that JQ1, a small molecule inhibitor of the BRD4 chromatin regulator, induces cell death in resistant cells, and gamma-secretase inhibitor plus JQ1 combination therapy prolongs cell survival in mice engrafted with primary human T-ALLs when compared to single-agent therapy. They suggest that drug resistance may be overcome with drugs that target epigenetic regulators.
doi: 10.1038/ng.2913
리서치 하이라이트
-
1월15일
Mental health: Suicide rate changes in Japan during COVID-19 pandemicNature Human Behaviour
-
1월13일
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
-
12월23일
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications
-
12월21일
Epidemiology: Underdetection of COVID-19 after the first lockdown in FranceNature
-
12월18일
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
-
12월17일
Epidemiology: Mapping gaps in measles vaccination coverageNature